straZeneca

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

集)	
*/pplication No.: 10/530,794	Applicant: Boyle et al
Filing Date: Not yet known	Attorney Docket No.: 100864-1P US
Examiner: Not yet known	Group Art Unit: Not yet known
Customer No.: 44992	Confirmation No.: Not yet known
Title: THERAPEUTIC TREATMENT	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 5, 2005

> Signature Lucy Padget

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir.

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

AstraZeneca R&D Boston

Tel +1 781-839-4000

A business unit of AstraZeneca Pharmaceuticals LP

Fax +1 781-839-4500

35 Gatehouse Drive Waltham MA 02451

Page 1 of 2